

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

Siklos 100 mg film-coated tablets.

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 100 mg of hydroxycarbamide.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Film-coated tablet (tablet).

Off-white round, film-coated tablet embossed 100 on one side.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic Sickle Cell Syndrome (see section 5.1).

### **4.2 Posology and method of administration**

Treatment with Siklos should be initiated by a physician experienced in the management of Sickle Cell Syndrome.

#### Posology

##### In adults, adolescents and children older than 2 years

The posology should be based on the patient's body weight (b.w.).

The starting dose of hydroxycarbamide is 15 mg/kg b.w. and the usual dose is between 15 and 30 mg/kg b.w./day.

As long as the patient responds to therapy either clinically or haematologically (e.g. increase of haemoglobin F (HbF), Mean Corpuscular Volume (MCV), neutrophil count) the dose of Siklos should be maintained.

In case of non-response (re-occurrence of crises or no decrease in crisis rate) the daily dose may be increased by steps of 2.5 to 5 mg/kg b.w./day using the most appropriate strength.

Under exceptional circumstances a maximum dose of 35 mg/kg b.w./day might be justified under close haematological monitoring (see section 4.4).

In the event a patient does still not respond when treated with the maximum dose of hydroxycarbamide (35 mg/kg b.w./day) over three to six months, permanent discontinuation of Siklos should be considered.

If blood counts are within the toxic range Siklos should be temporarily discontinued until blood counts recover. Haematologic recovery usually occurs within two weeks. Treatment may then be reinstated at a reduced dose. The dose of Siklos may then be increased again under close haematological monitoring. A dose producing haematological toxicity should not be tried more than two times.

The toxic range may be characterised by the following results of blood tests:

Neutrophils	< 2,000/mm <sup>3</sup>
Platelets	< 80,000/mm <sup>3</sup>

Haemoglobin	< 4.5 g/dl
Reticulocytes	< 80,000/mm <sup>3</sup> if the haemoglobin concentration < 9 g/dl

Long-term data on the continued use of hydroxycarbamide in patients with Sickle Cell Syndrome are available in children and adolescents, with a follow-up of 12 years in children and adolescents and over 13 years in adults. It is currently unknown how long patients should be treated with Siklos. The duration of treatment is the responsibility of the treating physician and should be based on the clinical and haematological status of the individual patient.

#### *Paediatric population*

##### Children less than 2 years of age

Because of the rarity of data on treatment with hydroxycarbamide in children less than 2 years of age, dose regimens have not been established and thus, in this population, the treatment with hydroxycarbamide is not recommended.

##### Children and adolescents (2-18 years old)

In children and adolescents with Sickle Cell Syndrome, systemic exposure to hydroxycarbamide is similar to adult patients. Hence, no dose-adjustments are necessary in younger patients.

##### Renal impairment

As renal excretion is a main pathway of elimination, dose reduction of Siklos should be considered in patients with renal impairment. In patients with a creatinine clearance  $\leq$  60 ml/min the initial Siklos dose should be decreased by 50%. Close monitoring of blood parameters is advised in these patients. Siklos should not be administered to patients with severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.3, 4.4 and 5.2).

##### Hepatic impairment

There are no data that support specific dose adjustments in patients with hepatic impairment. Close monitoring of blood parameters is advised in these patients. Due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 4.4).

##### Method of administration

Conforming to the individual dose, the tablet should be taken once daily, preferably in the morning before breakfast and, where necessary, with a glass of water or a very small amount of food.

For patients who are not able to swallow the tablets, these can be disintegrated **immediately before use** in a small quantity of water in a teaspoon. Adding a drop of syrup or mixing with food can mask a possible bitter taste.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients.

Severe hepatic impairment (Child-Pugh classification C) or severe renal impairment (creatinine clearance < 30 ml/min).

Toxic ranges of myelosuppression as described in section 4.2.

Breast-feeding (see section 4.6).

### **4.4 Special warnings and precautions for use**

Treatment with Siklos requires close clinical monitoring. The haematological status of the patient, as well as renal and hepatic functions should be determined prior to, and repeatedly during treatment. During treatment with Siklos, blood counts must be monitored every two weeks at treatment initiation (i.e. for the first two months) and if the daily dose of hydroxycarbamide is up to 35 mg/kg b.w. Patients who are stable on lower doses should be monitored every 2 months.

Treatment with Siklos should be discontinued if bone marrow function is markedly depressed. Neutropenia is generally the first and most common manifestation of haematological suppression. Thrombocytopenia and anaemia occur less frequently, and are rarely seen without a preceding neutropenia. Recovery from myelosuppression is usually rapid when therapy is discontinued. Siklos therapy can then be re-initiated at a lower dose (see section 4.2).

Siklos should be used with caution in patients with mild to moderate renal impairment (see section 4.2).

Since there is no available data in patients with mild to moderate liver impairment, Siklos should be used with caution.

In patients with leg ulcers, Siklos should be used with caution. Leg ulcers are a common complication of Sickle Cell Syndrome, but have also been reported in patients treated with hydroxycarbamide. Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxycarbamide should be discontinued and/or its dose reduced if cutaneous vasculitic ulcerations develop. Rarely, ulcers are caused by leukocytoclastic vasculitis.

Continuous follow-up of the growth of treated children is recommended.

Hydroxycarbamide causes macrocytosis, which may mask the incidental development of folic acid and vitamin B<sub>12</sub> deficiency. Prophylactic administration of folic acid is recommended.

Patients and/or parents or the legal responsible person must be able to follow directions regarding the administration of this medicinal product, their monitoring and care.

Hydroxycarbamide is unequivocally genotoxic in a wide range of test systems. Hydroxycarbamide is presumed to be a transspecies carcinogen. In patients receiving long-term hydroxycarbamide for myeloproliferative disorders, secondary leukaemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxycarbamide or is associated with the patient's underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxycarbamide.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Specific interaction studies have not been performed with hydroxycarbamide.

Potentially fatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxycarbamide in combination with antiretroviral medicinal products, particularly didanosine plus stavudine. Patients treated with hydroxycarbamide in combination with didanosine, stavudine, and indinavir showed a median decline in CD4 cells of approximately 100/mm<sup>3</sup>.

Concurrent use of hydroxycarbamide and other myelosuppressive medicinal products or radiation therapy may increase bone marrow depression, gastro-intestinal disturbances or mucositis. An erythema caused by radiation therapy may be aggravated by hydroxycarbamide.

Concomitant use of hydroxycarbamide with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase the adverse reaction of the vaccine virus, because normal defence mechanisms may be suppressed by hydroxycarbamide therapy. Vaccination with a live vaccine in a patient taking hydroxycarbamide may result in severe infections. Generally, the patient's antibody response to vaccines may be decreased. Treatment with Siklos and concomitant immunisation with live virus vaccines should only be performed if benefits clearly outweigh potential risks.

## **4.6 Fertility, pregnancy and lactation**

### Women of childbearing potential / Contraception in males and females

Women of childbearing age receiving hydroxycarbamide should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.

An effective method of contraception is strongly recommended in women of childbearing potential. Patients on hydroxycarbamide wishing to conceive should stop treatment 3 to 6 months before pregnancy if possible. The evaluation of the risk-benefit ratio should be made on an individual basis outweighing the respective risk of hydroxycarbamide therapy against the switch to a blood transfusion programme.

### Pregnancy

In the human, according to a retrospective analysis of a cohort of 123 adult patients treated with hydroxycarbamide, twenty-three pregnancies have been reported from 15 women treated with hydroxycarbamide and partners of 3 men treated with hydroxycarbamide. Most (61%) had a normal outcome with regard to term and normal birth. In the other cases with known evolution, pregnancy had been interrupted either voluntarily or upon medical advice. Thus the data on a limited number of exposed pregnancies indicate no adverse effects on pregnancy or on the health of the foetus/newborn. Studies in animals have shown reproductive toxicity (see section 5.3). Patients on hydroxycarbamide should be made aware of the theoretical risks to the foetus.

Based on the limited amount of available information, in case of an exposure to hydroxycarbamide of pregnant female patients or pregnant partners of male patients, treated by hydroxycarbamide, a careful follow-up with adequate clinical, biological and ultrasonographic examinations should be considered.

### Breastfeeding

Hydroxycarbamide is excreted in human milk. Because of the potential for serious adverse reactions in infants, breastfeeding must be discontinued while taking Siklos.

### Fertility

Fertility in males might be affected by treatment. Very common reversible oligo- and azoo-spermia have been observed in man, although these disorders are also associated with the underlying disease. Impaired fertility has been observed in male rats (see section 5.3).

## **4.7 Effects on ability to drive and use machines**

No studies on the effect on the ability to drive and use machines have been performed. However, patients should be informed that dizziness has been reported from literature, but not commonly. Patients should be advised not to drive or operate machines, if dizziness is experienced while taking Siklos.

## **4.8 Undesirable effects**

Specifically the safety of hydroxycarbamide had been examined retroactively from cohorts of 123 adults over 13 years and 352 children older than 2 years and adolescents up to 12 years.

The most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation. Bone marrow depression is the dose-limiting toxic effect of hydroxycarbamide. When the maximum tolerated dose is not reached transient myelotoxicity usually occurs in less than 10% of patients, while under the maximum tolerated dose more than 50% can experience reversible bone marrow suppression. These adverse reactions are expected based on the pharmacology of hydroxycarbamide. Gradual dose titration may help to diminish these effects (see section 4.2).

The adverse reactions are listed below by system organ class and absolute frequency. Frequencies are defined as very common ( $\geq 1/10$ ), common ( $>1/100$  to  $<1/10$ ), uncommon ( $>1/1,000$  to  $<1/100$ ), rare ( $>1/10,000$  to  $<1/1,000$ ), very rare ( $<1/10,000$ ), not known (cannot be estimated from the available

data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:

<i>Infections and infestations:</i>	
Not known:	Parvovirus B19 infection
<i>Neoplasms, benign, malignant and unspecified</i>	
Not known:	Leukaemia and in elderly patients, skin cancers
<i>Blood and lymphatic system disorders:</i>	
Very common:	Bone marrow depression <sup>1</sup> including neutropenia (< 2.0 x 10 <sup>9</sup> /l), reticulocytopenia (< 80 x 10 <sup>9</sup> /l), macrocytosis <sup>2</sup>
Common:	Thrombocytopenia (< 80 x 10 <sup>9</sup> /l), anaemia (haemoglobin < 4.5 g/dl) <sup>3</sup>
<i>Nervous system disorders:</i>	
Common:	Headache
Uncommon:	Dizziness
<i>Vascular disorders:</i>	
Not known:	Bleeding
<i>Gastrointestinal disorders:</i>	
Uncommon:	Nausea
Not known:	Gastrointestinal disturbances, vomiting, gastrointestinal ulcer, severe hypomagnesaemia
<i>Hepatobiliary disorders:</i>	
Rare:	Elevated liver enzymes
<i>Skin and subcutaneous tissue disorders:</i>	
Common	Skin reactions (for example oral, ungual and cutaneous pigmentation) and oral mucositis.
Uncommon:	Rash, melanonychia, alopecia
Rare:	Leg ulcers
Not known:	Cutaneous dryness
<i>Reproductive system and breast disorders:</i>	
Very common:	Oligospermia , azoospermia <sup>4</sup>
Not known:	Amenorrhea
<i>General disorders and administration site conditions:</i>	
Not known:	Fever
<i>Investigations:</i>	
Not known:	Weight gain <sup>5</sup>

<sup>1</sup> Haematological recovery usually occurs within two weeks of withdrawal of hydroxycarbamide.

<sup>2</sup> The macrocytosis caused by hydroxycarbamide is not vitamin B<sub>12</sub> or folic acid dependent.

<sup>3</sup> Mainly due to an infection with Parvovirus or a splenic sequestration.

<sup>4</sup> Oligospermia and azoospermia are in general reversible, but have to be taken into account when fatherhood is desired (see section 5.3). These disorders are also associated with the underlying disease.

<sup>5</sup> Weight gain may be an effect of improved general conditions.

The clinical data obtained in patients with Sickle Cell Syndrome have not shown evidence of adverse reactions of hydroxycarbamide on hepatic and renal function.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#)

#### 4.9 Overdose

Acute mucocutaneous toxicity has been reported in patients receiving hydroxycarbamide at doses

several times above the therapeutic dose. Soreness, violet erythema, oedema on palms and soles followed by scaling of hand and feet, severe generalised hyperpigmentation of the skin and stomatitis have been observed.

In patients with Sickle Cell Syndrome, neutropenia was reported in isolated cases of hydroxycarbamide overdose (1.43 times and 8.57 times of the maximum recommended dose of 35 mg/kg b.w./day). It is recommended that blood counts are monitored for several weeks after overdose since recovery may be delayed.

Treatment of overdose consists of gastric lavage, followed by symptomatic treatment and control of bone marrow function.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX05.

In nearly all clinical studies conducted in Sickle Cell Syndrome, hydroxycarbamide reduced the frequency of vaso-occlusive episodes by 66% to 80%, in children and in adults. The same decrease was observed for the number of hospital admissions and the number of days of hospitalisation in the treated groups. The yearly frequency of acute chest syndrome was also reduced by 25 to 33% under hydroxycarbamide in several studies. Acute chest syndrome is a frequent life-threatening complication of Sickle Cell Syndrome and is characterised by chest pain or fever or dyspnoea with recent infiltrate on chest X-ray.

A sustained clinical benefit was demonstrated in patients remaining on hydroxycarbamide treatment for up to 8 years.

The specific mechanism of action of hydroxycarbamide is not fully understood. One of the mechanisms by which hydroxycarbamide acts is the elevation of foetal haemoglobin (HbF) concentrations in sickle cell patients. HbF interferes with the polymerisation of HbS and thus impedes the sickling of red blood cell. In all clinical studies, there was a significant increase in HbF from baseline after hydroxycarbamide use.

Recently, hydroxycarbamide has shown to be associated with the generation of nitric oxide suggesting that nitric oxide stimulates cyclic guanosine monophosphatase (cGMP) production, which then activates a protein kinase and increases the production of HbF. Other known pharmacological effects of hydroxycarbamide which may contribute to its beneficial effects in Sickle Cell Syndrome include decrease of neutrophils, increase of the water content of erythrocytes, increase of the deformability of sickled cells, and altered adhesion of red blood cells to the endothelium.

In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.

Beside the inconstant correlation between reduction of crisis rate and the increase in HbF, the cytoreductive effect of hydroxycarbamide, particularly the drop of neutrophils, was the factor with the strongest correlation to a reduced crisis rate.

### 5.2 Pharmacokinetic properties

#### Absorption

After oral administration of 20 mg/kg of hydroxycarbamide, a rapid absorption is observed with peak plasma levels of about 30 mg/l occurring after 0.75 and 1.2 h in children and adult patients with Sickle Cell Syndrome, respectively. The total exposure up to 24 h post-dose is 124 mg\*h/l in children and adolescents and 135 mg\*h/l in adult patients. The oral bioavailability of hydroxycarbamide is almost complete as assessed in indications other than Sickle Cell Syndrome.

### Distribution

Hydroxycarbamide distributes rapidly throughout the human body, enters the cerebrospinal fluid, appears in peritoneal fluid and ascites, and concentrates in leukocytes and erythrocytes. The estimated volume of distribution of hydroxycarbamide approximates total body water. The volume of distribution at steady state adjusted for bioavailability is 0.57 l/kg in patients with Sickle Cell Syndrome (amounting to approximately 72 and 90 l in children and adults, respectively). The extent of protein binding of hydroxycarbamide is unknown.

### Biotransformation

The biotransformation pathways as well as the metabolites are not fully characterised. Urea is one metabolite of hydroxycarbamide.

Hydroxycarbamide at 30, 100 and 300 µM is not metabolised in vitro by cytochrome P450s of human liver microsomes. At concentrations ranging from 10 to 300 µM, hydroxycarbamide does not stimulate the in vitro ATPase activity of recombinant human P glycoprotein (PGP), indicating that hydroxycarbamide is not a PGP substrate. Hence, no interaction is to be expected in case of concomitant administration with substances being substrates of cytochromes P450 or P-glycoprotein.

### Elimination

In a repeated dose study in adult patients with Sickle Cell Syndrome approximately 60% of the hydroxycarbamide dose was detected in urine at steady state. In adults the total clearance adjusted for bioavailability was 9.89 l/h (0.16 l/h/kg) thereof 5.64 and 4.25 l/h by renal and non-renal clearance, respectively. The respective value for total clearance in children was 7.25 l/h (0.20 l/h/kg) with 2.91 and 4.34 l/h by renal and non-renal pathways.

In adults with Sickle Cell Syndrome, mean cumulative urinary hydroxycarbamide excretion was 62% of the administered dose at 8 hours, and thus higher than in cancer patients (35–40%). In patients with Sickle Cell Syndrome hydroxycarbamide was eliminated with a half-life of approximately six to seven hours, which is longer than reported in other indications.

### Geriatric, gender, race

No information is available regarding pharmacokinetic differences due to age (except paediatric patients), gender or race.

### Paediatric population

In paediatric and adult patients with Sickle Cell Syndrome the systemic exposure to hydroxycarbamide at steady state was similar by means of the area under the curve. The maximum plasma levels and the apparent volume of distribution related to body weight were well comparable between age groups. The time to reach maximum plasma concentration and the percentage of the dose excreted in urine were increased in children compared to adults. In paediatric patients the half-life was slightly longer and the total clearance related to body weight slightly higher than in adult patients (see section 4.2).

### Renal impairment

As renal excretion is a pathway of elimination, consideration should be given to decreasing the dose of Siklos in patients with renal impairment. In an open single-dose study in adult patients with Sickle Cell Syndrome (*Yan JH et al, 2005*) the influence of renal function on pharmacokinetics of hydroxycarbamide was assessed. Patients with normal (creatinine clearance CrCl>80 ml/min), mild (CrCl 60–80 ml/min), moderate (CrCl 30 - 60 ml/min), or severe (<30 ml/min) renal impairment received hydroxycarbamide as a single dose of 15 mg/kg b.w. by using 200 mg, 300 mg, or 400 mg capsules. In patients, whose CrCl was below 60 ml/min or patients with end-stage renal disease the mean exposure to hydroxycarbamide was approximately 64% higher than in patients with normal renal function. As evaluated in a further study, in patients with a CrCl<60 ml/min the area under the curve was approximately 51% higher than in patients with a CrCl ≥60 ml/min, which suggests that a dose reduction of hydroxycarbamide by 50% may be appropriate in patients with a CrCl ≤ 60 ml/min. Haemodialysis reduced the exposure to hydroxycarbamide by 33% (see sections 4.2 and 4.4).

Close monitoring of blood parameters is advised in these patients.

### Hepatic impairment

There are no data that support specific guidance for dose adjustment in patients with hepatic impairment, but, due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see section 4.3). Close monitoring of blood parameters is advised in patients with hepatic impairment.

### **5.3 Preclinical safety data**

In preclinical toxicity studies the most common effects noted included bone marrow depression, lymphoid atrophy and degenerative changes in the epithelium of the small and large intestines. Cardiovascular effects and haematological changes were observed in some species. Also, in rats testicular atrophy with decreased spermatogenesis occurred, while in dogs reversible spermatogenic arrest was noted.

Hydroxycarbamide is unequivocally genotoxic in a wide range of test systems. Conventional long-term studies to evaluate the carcinogenic potential of hydroxycarbamide have not been performed. However, hydroxycarbamide is presumed to be a transspecies carcinogen.

Hydroxycarbamide crosses the placenta barrier and has been demonstrated to be a potent teratogen and embryotoxic in a wide variety of animal models at or below the human therapeutic dose. Teratogenicity was characterised by partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae. Embryotoxicity was characterized by decreased foetal viability, reduced live litter sizes, and developmental delays..

Hydroxycarbamide administered to male rats at 60 mg/kg b.w./day (about double the recommended usual maximum dose in humans) produced testicular atrophy, decreased spermatogenesis and significantly reduced their ability to impregnate females.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium stearyl fumarate  
Silicified microcrystalline cellulose  
Basic butylated methacrylate copolymer

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

3 years.

### **6.4 Special precautions for storage**

Store below 30°C.

### **6.5 Nature and contents of container**

High density polyethylene (HDPE) bottle with polypropylene child-resistant cap with a dessicant unit containing 60, 90 or 120 film coated tablets.

Not all pack sizes may be marketed.

## **6.6 Special precautions for disposal and other handling**

Siklos is a medicinal product that must be handled with care. People who are not taking Siklos and in particular pregnant women should avoid being in contact with hydroxycarbamide.  
Anyone handling Siklos should wash their hands before and after contact with the tablets.  
Any unused product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Addmedica  
101 rue Saint Lazare  
75009 Paris  
France  
Phone: +33 1 72 69 01 86  
Fax: +33 1 73 72 94 13  
E-mail : [contact@addmedica.com](mailto:contact@addmedica.com)

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/07/397/002  
EU/1/07/397/003  
EU/1/07/397/004

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 29/06/2007

Date of latest renewal: 28/06/2012

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency: <http://www.ema.europa.eu>.

## **1. NAME OF THE MEDICINAL PRODUCT**

Siklos 1000 mg film-coated tablets.

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 1,000 mg of hydroxycarbamide.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Film-coated tablet (tablet).

Off-white, capsule-shaped, film-coated tablet with triple scoring on both sides.  
The tablet can be divided into four equal parts.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic Sickle Cell Syndrome (see section 5.1).

### **4.2 Posology and method of administration**

Treatment with Siklos should be initiated by a physician experienced in the management of Sickle Cell Syndrome.

#### Posology

##### In adults, adolescents and children older than 2 years

The posology should be based on the patient's body weight (b.w.).

The starting dose of hydroxycarbamide is 15 mg/kg b.w. and the usual dose is between 15 and 30 mg/kg b.w./day.

As long as the patient responds to therapy either clinically or haematologically (e.g. increase of haemoglobin F (HbF), Mean Corpuscular Volume (MCV), neutrophil count) the dose of Siklos should be maintained.

In case of non-response (re-occurrence of crises or no decrease in crisis rate) the daily dose may be increased by steps of 2.5 to 5 mg/kg b.w./day using the most appropriate strength.

Under exceptional circumstances a maximum dose of 35 mg/kg b.w./day might be justified under close haematological monitoring (see section 4.4).

In the event a patient does still not respond when treated with the maximum dose of hydroxycarbamide (35 mg/kg b.w./day) over three to six months, permanent discontinuation of Siklos should be considered.

If blood counts are within the toxic range Siklos should be temporarily discontinued until blood counts recover. Haematologic recovery usually occurs within two weeks. Treatment may then be reinstated at a reduced dose. The dose of Siklos may then be increased again under close haematological monitoring. A dose producing haematological toxicity should not be tried more than two times.

The toxic range may be characterised by the following results of blood tests:

Neutrophils      < 2,000/mm<sup>3</sup>

Platelets	< 80,000/mm <sup>3</sup>
Haemoglobin	< 4.5 g/dl
Reticulocytes	< 80,000/mm <sup>3</sup> if the haemoglobin concentration <9 g/dl

Long-term data on the continued use of hydroxycarbamide in patients with Sickle Cell Syndrome are available in children and adolescents, with a follow-up of 12 years in children and adolescents and over 13 years in adults. It is currently unknown how long patients should be treated with Siklos. The duration of treatment is the responsibility of the treating physician and should be based on the clinical and haematological status of the individual patient.

#### *Paediatric population*

##### Children less than 2 years of age

Because of the rarity of data on treatment with hydroxycarbamide in children less than 2 years of age, dose regimens have not been established and thus, in this population, the treatment with hydroxycarbamide is not recommended.

##### Children and adolescents (2-18 years old)

In children and adolescents with Sickle Cell Syndrome, systemic exposure to hydroxycarbamide is similar to adult patients. Hence, no dose-adjustments are necessary in younger patients.

##### Renal impairment

As renal excretion is a main pathway of elimination, dose reduction of Siklos should be considered in patients with renal impairment. In patients with a creatinine clearance  $\leq$  60 ml/min the initial Siklos dose should be decreased by 50%. Close monitoring of blood parameters is advised in these patients. Siklos should not be administered to patients with severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.3, 4.4 and 5.2).

##### Hepatic impairment

There are no data that support specific dose adjustments in patients with hepatic impairment. Close monitoring of blood parameters is advised in these patients. Due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 4.4).

##### Method of administration

Conforming to the individual dose, the tablet or the halves or quarters of the tablet should be taken once daily, preferably in the morning before breakfast and, where necessary, with a glass of water or a very small amount of food.

For patients who are not able to swallow the tablets, these can be disintegrated **immediately before use** in a small quantity of water in a teaspoon. Adding a drop of syrup or mixing with food can mask a possible bitter taste.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients.

Severe hepatic impairment (Child-Pugh classification C) or severe renal impairment (creatinine clearance < 30 ml/min).

Toxic ranges of myelosuppression as described in section 4.2.

Breast-feeding (see section 4.6).

### **4.4 Special warnings and precautions for use**

Treatment with Siklos requires close clinical monitoring. The haematological status of the patient, as well as renal and hepatic functions should be determined prior to, and repeatedly during treatment. During treatment with Siklos, blood counts must be monitored every two weeks at treatment initiation

(i.e. for the first two months) and if the daily dose of hydroxycarbamide is up to 35 mg/kg b.w. Patients who are stable on lower doses should be monitored every 2 months.

Treatment with Siklos should be discontinued if bone marrow function is markedly depressed. Neutropenia is generally the first and most common manifestation of haematological suppression. Thrombocytopenia and anaemia occur less frequently, and are rarely seen without a preceding neutropenia. Recovery from myelosuppression is usually rapid when therapy is discontinued. Siklos therapy can then be re-initiated at a lower dose (see section 4.2).

Siklos should be used with caution in patients with mild to moderate renal impairment (see section 4.2).

Since there is no available data in patients with mild to moderate liver impairment, Siklos should be used with caution.

In patients with leg ulcers, Siklos should be used with caution. Leg ulcers are a common complication of Sickle Cell Syndrome, but have also been reported in patients treated with hydroxycarbamide. Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxycarbamide should be discontinued and/or its dose reduced if cutaneous vasculitic ulcerations develop. Rarely, ulcers are caused by leukocytoclastic vasculitis.

Continuous follow-up of the growth of treated children is recommended.

Hydroxycarbamide causes macrocytosis, which may mask the incidental development of folic acid and vitamin B<sub>12</sub> deficiency. Prophylactic administration of folic acid is recommended.

Patients and/or parents or the legal responsible person must be able to follow directions regarding the administration of this medicinal product, their monitoring and care.

Hydroxycarbamide is unequivocally genotoxic in a wide range of test systems. Hydroxycarbamide is presumed to be a transspecies carcinogen. In patients receiving long-term hydroxycarbamide for myeloproliferative disorders, secondary leukaemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxycarbamide or is associated with the patient's underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxycarbamide.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Specific interaction studies have not been performed with hydroxycarbamide.

Potentially fatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxycarbamide in combination with antiretroviral medicinal products, particularly didanosine plus stavudine. Patients treated with hydroxycarbamide in combination with didanosine, stavudine, and indinavir showed a median decline in CD4 cells of approximately 100/mm<sup>3</sup>.

Concurrent use of hydroxycarbamide and other myelosuppressive medicinal products or radiation therapy may increase bone marrow depression, gastro-intestinal disturbances or mucositis. An erythema caused by radiation therapy may be aggravated by hydroxycarbamide.

Concomitant use of hydroxycarbamide with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase the adverse reaction of the vaccine virus, because normal defence mechanisms may be suppressed by hydroxycarbamide therapy. Vaccination with a live vaccine in a patient taking hydroxycarbamide may result in severe infections. Generally, the patient's antibody response to vaccines may be decreased. Treatment with Siklos and concomitant immunisation with live virus vaccines should only be performed if benefits clearly outweigh potential risks.

## **4.6 Fertility, pregnancy and lactation**

### Women of childbearing potential / Contraception in males and females

Women of childbearing age receiving hydroxycarbamide should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.

An effective method of contraception is strongly recommended in women of childbearing potential. Patients on hydroxycarbamide wishing to conceive should stop treatment 3 to 6 months before pregnancy if possible. The evaluation of the risk-benefit ratio should be made on an individual basis outweighing the respective risk of hydroxycarbamide therapy against the switch to a blood transfusion programme.

### Pregnancy

In the human, according to a retrospective analysis of a cohort of 123 adult patients treated with hydroxycarbamide, twenty-three pregnancies have been reported from 15 women treated with hydroxycarbamide and partners of 3 men treated with hydroxycarbamide. Most (61%) had a normal outcome with regard to term and normal birth. In the other cases with known evolution, pregnancy had been interrupted either voluntarily or upon medical advice. Thus the data on a limited number of exposed pregnancies indicate no adverse effects on pregnancy or on the health of the foetus/newborn. Studies in animals have shown reproductive toxicity (see section 5.3). Patients on hydroxycarbamide should be made aware of the theoretical risks to the foetus.

Based on the limited amount of available information, in case of an exposure to hydroxycarbamide of pregnant female patients or pregnant partners of male patients, treated by hydroxycarbamide, a careful follow-up with adequate clinical, biological and ultrasonographic examinations should be considered.

### Breastfeeding

Hydroxycarbamide is excreted in human milk. Because of the potential for serious adverse reactions in infants, breastfeeding must be discontinued while taking Siklos.

### Fertility

Fertility in males might be affected by treatment. Very common reversible oligo- and azo-spermia have been observed in man, although these disorders are also associated with the underlying disease. Impaired fertility has been observed in male rats (see section 5.3).

## **4.7 Effects on ability to drive and use machines**

No studies on the effect on the ability to drive and use machines have been performed. However, patients should be informed that dizziness has been reported from literature, but not commonly. Patients should be advised not to drive or operate machines, if dizziness is experienced while taking Siklos.

## **4.8 Undesirable effects**

Specifically the safety of hydroxycarbamide had been examined retroactively from cohorts of 123 adults over 13 years and 352 children older than 2 years and adolescents up to 12 years.

The most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation. Bone marrow depression is the dose-limiting toxic effect of hydroxycarbamide. When the maximum tolerated dose is not reached transient myelotoxicity usually occurs in less than 10% of patients, while under the maximum tolerated dose more than 50% can experience reversible bone marrow suppression. These adverse reactions are expected based on the pharmacology of hydroxycarbamide. Gradual dose titration may help to diminish these effects (see section 4.2).

The adverse reactions are listed below by system organ class and absolute frequency. Frequencies are defined as very common ( $\geq 1/10$ ), common ( $>1/100$  to  $<1/10$ ), uncommon ( $>1/1,000$  to  $<1/100$ ), rare

(>1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:

<i>Infections and infestations:</i>	
Not known:	Parvovirus B19 infection
<i>Neoplasms, benign, malignant and unspecified</i>	
Not known:	Leukaemia and in elderly patients, skin cancers
<i>Blood and lymphatic system disorders:</i>	
Very common:	Bone marrow depression <sup>1</sup> including neutropenia (< 2.0 x 10 <sup>9</sup> /l), reticulocytopenia (< 80 x 10 <sup>9</sup> /l), macrocytosis <sup>2</sup>
Common:	Thrombocytopenia (< 80 x 10 <sup>9</sup> /l), anaemia (haemoglobin < 4.5 g/dl) <sup>3</sup>
<i>Nervous system disorders:</i>	
Common:	Headache
Uncommon:	Dizziness
<i>Vascular disorders:</i>	
Not known:	Bleeding
<i>Gastrointestinal disorders:</i>	
Uncommon:	Nausea
Not known:	Gastrointestinal disturbances, vomiting, gastrointestinal ulcer, severe hypomagnesaemia
<i>Hepatobiliary disorders:</i>	
Rare:	Elevated liver enzymes
<i>Skin and subcutaneous tissue disorders:</i>	
Common	Skin reactions (for example oral, ungual and cutaneous pigmentation) and oral mucositis.
Uncommon:	Rash, melanonychia, alopecia
Rare:	Leg ulcers
Not known:	Cutaneous dryness
<i>Reproductive system and breast disorders:</i>	
Very common:	Oligospermia,azoospermia <sup>4</sup>
Not known:	Amenorrhea
<i>General disorders and administration site conditions:</i>	
Not known:	Fever
<i>Investigations:</i>	
Not known:	Weight gain <sup>5</sup>

<sup>1</sup> Haematological recovery usually occurs within two weeks of withdrawal of hydroxycarbamide.

<sup>2</sup> The macrocytosis caused by hydroxycarbamide is not vitamin B<sub>12</sub> or folic acid dependent.

<sup>3</sup> Mainly due to an infection with Parvovirus or a splenic sequestration.

<sup>4</sup> Oligospermia and azoospermia are in general reversible, but have to be taken into account when fatherhood is desired (see section 5.3). These disorders are also associated with the underlying disease.

<sup>5</sup> Weight gain may be an effect of improved general conditions.

The clinical data obtained in patients with Sickle Cell Syndrome have not shown evidence of adverse reactions of hydroxycarbamide on hepatic and renal function.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#)

#### **4.9 Overdose**

Acute mucocutaneous toxicity has been reported in patients receiving hydroxycarbamide at doses several times above the therapeutic dose. Soreness, violet erythema, oedema on palms and soles

followed by scaling of hand and feet, severe generalised hyperpigmentation of the skin and stomatitis have been observed.

In patients with Sickle Cell Syndrome, neutropenia was reported in isolated cases of hydroxycarbamide overdose (1.43 times and 8.57 times of the maximum recommended dose of 35 mg/kg b.w./day). It is recommended that blood counts are monitored for several weeks after overdose since recovery may be delayed.

Treatment of overdose consists of gastric lavage, followed by symptomatic treatment and control of bone marrow function.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX05.

In nearly all clinical studies conducted in Sickle Cell Syndrome, hydroxycarbamide reduced the frequency of vaso-occlusive episodes by 66% to 80%, in children and in adults. The same decrease was observed for the number of hospital admissions and the number of days of hospitalisation in the treated groups. The yearly frequency of acute chest syndrome was also reduced by 25 to 33% under hydroxycarbamide in several studies. Acute chest syndrome is a frequent life-threatening complication of Sickle Cell Syndrome and is characterised by chest pain or fever or dyspnoea with recent infiltrate on chest X-ray.

A sustained clinical benefit was demonstrated in patients remaining on hydroxycarbamide treatment for up to 8 years.

The specific mechanism of action of hydroxycarbamide is not fully understood. One of the mechanisms by which hydroxycarbamide acts is the elevation of foetal haemoglobin (HbF) concentrations in sickle cell patients. HbF interferes with the polymerisation of HbS and thus impedes the sickling of red blood cell. In all clinical studies, there was a significant increase in HbF from baseline after hydroxycarbamide use.

Recently, hydroxycarbamide has shown to be associated with the generation of nitric oxide suggesting that nitric oxide stimulates cyclic guanosine monophosphatase (cGMP) production, which then activates a protein kinase and increases the production of HbF. Other known pharmacological effects of hydroxycarbamide which may contribute to its beneficial effects in Sickle Cell Syndrome include decrease of neutrophils, increase of the water content of erythrocytes, increase of the deformability of sickled cells, and altered adhesion of red blood cells to the endothelium.

In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.

Beside the inconstant correlation between reduction of crisis rate and the increase in HbF, the cytoreductive effect of hydroxycarbamide, particularly the drop of neutrophils, was the factor with the strongest correlation to a reduced crisis rate.

### 5.2 Pharmacokinetic properties

#### Absorption

After oral administration of 20 mg/kg of hydroxycarbamide, a rapid absorption is observed with peak plasma levels of about 30 mg/l occurring after 0.75 and 1.2 h in children and adult patients with Sickle Cell Syndrome, respectively. The total exposure up to 24 h post-dose is 124 mg\*h/l in children and adolescents and 135 mg\*h/l in adult patients. The oral bioavailability of hydroxycarbamide is almost complete as assessed in indications other than Sickle Cell Syndrome.

### Distribution

Hydroxycarbamide distributes rapidly throughout the human body, enters the cerebrospinal fluid, appears in peritoneal fluid and ascites, and concentrates in leukocytes and erythrocytes. The estimated volume of distribution of hydroxycarbamide approximates total body water. The volume of distribution at steady state adjusted for bioavailability is 0.57 l/kg in patients with Sickle Cell Syndrome (amounting to approximately 72 and 90 l in children and adults, respectively). The extent of protein binding of hydroxycarbamide is unknown.

### Biotransformation

The biotransformation pathways as well as the metabolites are not fully characterised. Urea is one metabolite of hydroxycarbamide.

Hydroxycarbamide at 30, 100 and 300 µM is not metabolised in vitro by cytochrome P450s of human liver microsomes. At concentrations ranging from 10 to 300 µM, hydroxycarbamide does not stimulate the in vitro ATPase activity of recombinant human P glycoprotein (PGP), indicating that hydroxycarbamide is not a PGP substrate. Hence, no interaction is to be expected in case of concomitant administration with substances being substrates of cytochromes P450 or P-glycoprotein.

### Elimination

In a repeated dose study in adult patients with Sickle Cell Syndrome approximately 60% of the hydroxycarbamide dose was detected in urine at steady state. In adults the total clearance adjusted for bioavailability was 9.89 l/h (0.16 l/h/kg) thereof 5.64 and 4.25 l/h by renal and non-renal clearance, respectively. The respective value for total clearance in children was 7.25 l/h (0.20 l/h/kg) with 2.91 and 4.34 l/h by renal and non-renal pathways.

In adults with Sickle Cell Syndrome, mean cumulative urinary hydroxycarbamide excretion was 62% of the administered dose at 8 hours, and thus higher than in cancer patients (35–40%). In patients with Sickle Cell Syndrome hydroxycarbamide was eliminated with a half-life of approximately six to seven hours, which is longer than reported in other indications.

### Geriatric, gender, race

No information is available regarding pharmacokinetic differences due to age (except paediatric patients), gender or race.

### Paediatric population

In paediatric and adult patients with Sickle Cell Syndrome the systemic exposure to hydroxycarbamide at steady state was similar by means of the area under the curve. The maximum plasma levels and the apparent volume of distribution related to body weight were well comparable between age groups. The time to reach maximum plasma concentration and the percentage of the dose excreted in urine were increased in children compared to adults. In paediatric patients the half-life was slightly longer and the total clearance related to body weight slightly higher than in adult patients (see section 4.2).

### Renal impairment

As renal excretion is a pathway of elimination, consideration should be given to decreasing the dose of Siklos in patients with renal impairment. In an open single-dose study in adult patients with Sickle Cell Syndrome (*Yan JH et al, 2005*) the influence of renal function on pharmacokinetics of hydroxycarbamide was assessed. Patients with normal (creatinine clearance CrCl>80 ml/min), mild (CrCl 60–80 ml/min), moderate (CrCl 30 - 60 ml/min), or severe (<30 ml/min) renal impairment received hydroxycarbamide as a single dose of 15 mg/kg b.w. by using 200 mg, 300 mg, or 400 mg capsules. In patients, whose CrCl was below 60 ml/min or patients with end-stage renal disease the mean exposure to hydroxycarbamide was approximately 64% higher than in patients with normal renal function. As evaluated in a further study, in patients with a CrCl<60 ml/min the area under the curve was approximately 51% higher than in patients with a CrCl ≥60 ml/min, which suggests that a dose reduction of hydroxycarbamide by 50% may be appropriate in patients with a CrCl ≤ 60 ml/min. Haemodialysis reduced the exposure to hydroxycarbamide by 33% (see sections 4.2 and 4.4) Close monitoring of blood parameters is advised in these patients.

### Hepatic impairment

There are no data that support specific guidance for dose adjustment in patients with hepatic impairment, but, due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see section 4.3). Close monitoring of blood parameters is advised in patients with hepatic impairment.

### **5.3 Preclinical safety data**

In preclinical toxicity studies the most common effects noted included bone marrow depression, lymphoid atrophy and degenerative changes in the epithelium of the small and large intestines. Cardiovascular effects and haematological changes were observed in some species. Also, in rats testicular atrophy with decreased spermatogenesis occurred, while in dogs reversible spermatogenic arrest was noted.

Hydroxycarbamide is unequivocally genotoxic in a wide range of test systems. Conventional long-term studies to evaluate the carcinogenic potential of hydroxycarbamide have not been performed. However, hydroxycarbamide is presumed to be a transspecies carcinogen.

Hydroxycarbamide crosses the placenta barrier and has been demonstrated to be a potent teratogen and embryotoxic in a wide variety of animal models at or below the human therapeutic dose. Teratogenicity was characterised by partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae. Embryotoxicity was characterized by decreased foetal viability, reduced live litter sizes, and developmental delays.

Hydroxycarbamide administered to male rats at 60 mg/kg b.w./day (about double the recommended usual maximum dose in humans) produced testicular atrophy, decreased spermatogenesis and significantly reduced their ability to impregnate females.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium stearyl fumarate  
Silicified microcrystalline cellulose  
Basic butylated methacrylate copolymer

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

3 years.  
In-use stability shelf-life: Unused Siklos 1000 mg broken tablets must be replaced in the bottle and must be used within three months”

### **6.4 Special precautions for storage**

Store below 30°C.  
For storage of unused broken tablets see section 6.3

### **6.5 Nature and contents of container**

High density polyethylene (HDPE) bottle with polypropylene child-resistant cap with a dessicant unit.  
Pack size: 30 film-coated tablets.

## **6.6 Special precautions for disposal and other handling**

Siklos is a medicinal product that must be handled with care. People who are not taking Siklos and in particular pregnant women should avoid being in contact with hydroxycarbamide.

In case the prescribed dose requires breaking the tablet in halves or quarters, this should be done out of the reach of food. Powder eventually spilled from the broken tablet should be wiped up with a damp disposable towel, which must be discarded. Anyone handling Siklos should wash their hands before and after contact with the tablets.

Any unused product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Addmedica  
101 rue Saint Lazare  
75009 Paris  
France  
Phone: +33 1 72 69 01 86  
Fax: +33 1 73 72 94 13  
E-mail: [contact@addmedica.com](mailto:contact@addmedica.com)

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/07/397/001

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 29/06/2007

Date of latest renewal: 28/06/2012

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency: <http://www.ema.europa.eu>.

## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

## **A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

Delpharm Lille  
Z.I de Roubaix Est  
Rue de Toufflers  
59390 Lys-Lez-Lannoy  
France

## **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

## **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- Periodic Safety Update Reports**

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## **D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- Risk Management Plan (RMP)**

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

An updated RMP shall be submitted on a yearly basis .

- Additional risk minimisation measures**

The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe Siklos are provided with a physician information pack containing the following:

- Treatment guide for physicians
- Patient information pack

The treatment guide for physicians should contain the following key elements:

- The Summary of Product Characteristics
- Need for periodic blood counts and dose adjustment
- Need for contraception
- Risk to male and female fertility, potential risk to foetus and breast feeding
- Growth follow-up of treated children
- Handling of broken tablets
- Management of adverse drug reactions
- Risk of medication error due to the availability of two different strengths

The patient information pack should contain the following key elements:

- Package leaflet
- Handling of broken tablets
- Need for periodic blood counts
- Information on crisis or infections
- Need for contraception
- Risk to male and female fertility, potential risk to foetus and breast feeding
- Key signs and symptoms of serious adverse reactions
- When to seek urgent attention from the health care provider
- Information on growth follow-up of treated children for their parents
- Risk of medication error due to the availability of two different strengths

The MAH must implement this educational plan nationally, prior to marketing, and as agreed with the competent authorities in the Member States

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING****CARTON****1. NAME OF THE MEDICINAL PRODUCT**

Siklos 100 mg film-coated tablets  
hydroxycarbamide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 100 mg of hydroxycarbamide.

**3. LIST OF EXCIPIENTS****4. PHARMACEUTICAL FORM AND CONTENTS**

60 tablets  
90 tablets  
120 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Handle tablets with care.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store below 30 °C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS**

**OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Addmedica, 101 rue Saint Lazare – 75009 Paris - France

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/07/397/002 60 tablets

EU/1/07/397/003 90 tablets

EU/1/07/397/004 120 tablets

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

siklos 100 mg

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING****CARTON****1. NAME OF THE MEDICINAL PRODUCT**

Siklos 1000 mg film-coated tablets  
hydroxycarbamide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 1,000 mg of hydroxycarbamide.

**3. LIST OF EXCIPIENTS****4. PHARMACEUTICAL FORM AND CONTENTS**

30 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Handle tablets with care.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store below 30 °C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Addmedica, 101 rue Saint Lazare – 75009 Paris - France

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/07/397/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

siklos 1000 mg

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BOTTLE**

**1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

Siklos 100 mg tablets  
hydroxycarbamide  
Oral use

**2. METHOD OF ADMINISTRATION**

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

60 tablets  
90 tablets  
120 tablets

**6. OTHER**

Addmedica

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING****BOTTLE****1. NAME OF THE MEDICINAL PRODUCT**

Siklos 1000 mg tablets  
hydroxycarbamide

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 1,000 mg of hydroxycarbamide.

**3. LIST OF EXCIPIENTS****4. PHARMACEUTICAL FORM AND CONTENTS**

30 tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

Handle tablets with care.

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store below 30 °C.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Addmedica

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/07/397/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY****15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

**B. PACKAGE LEAFLET**

## **Package leaflet: information for the user**

**Siklos 100 mg film-coated tablets**  
**Siklos 1000 mg film-coated tablets**  
hydroxycarbamide

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, or pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

### **What is in this leaflet**

1. What Siklos is and what it is used for
2. What you need to know before you take Siklos
3. How to take Siklos
4. Possible side effects
5. How to store Siklos
6. Contents of the pack and other information

### **1. What Siklos is and what it is used for**

Siklos is used to prevent painful crises, including sudden chest pain, caused by Sickle Cell disease, in adults, adolescents and children older than 2 years .

Sickle Cell disease is an inherited blood disorder that affects the disc shaped red cells of the blood. Some cells become abnormal, rigid and take a crescent or sickle shape which leads to anemia.

The sickle cells also get stuck in blood vessels, blocking blood flow. This can cause acute pain crises and organ damage.

For severe painful crises, most patients require hospitalisations. Siklos will decrease the number of painful crises as well as the need for hospitalisation linked with the disease.

The active substance of Siklos, i.e. hydroxycarbamide, is a substance which inhibits growth and proliferation of some cells, such as blood cells. These effects lead to a reduction of circulating red, white and coagulation blood cells (myelosuppressive effect). In Sickle Cell disease, hydroxycarbamide helps also to prevent red blood cells from taking abnormal shape.

### **2. What you need to know before you take Siklos**

#### **Do not take Siklos**

- if you are allergic (hypersensitive) to hydroxycarbamide or any of the other ingredients of Siklos, (see section “further information”),
- if you suffer from severe liver disease,
- if you suffer from severe kidney disease,
- if you are myelosuppressed (if you have decreased production of red, white, or coagulating blood cells) as described in the section “how to take siklos” (treatment follow-up),
- if you are breast-feeding (see section “Pregnancy and breast-feeding”).

## **Warnings and precautions**

Talk to your doctor or pharmacist or nurse before taking Siklos

- if you have a liver disease,
- if you have a kidney disease,
- if you have leg ulcers,
- if you are taking other myelosuppressive medicines (decrease production of red, white, or coagulating blood cells) or receiving radiation therapy,
- if you have a known lack of vitamin B12 or folate.

If you experience (or have experienced) any of the above, please tell your doctor. If you have any question please ask your doctor or pharmacist or nurse.

## **Children and adolescents**

Patients and/or parents or the legal responsible person must be able to follow directions regarding the administration of this medicinal product, their monitoring and care.

## **Other medicines and Siklos**

Please inform your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

- antiretroviral medicines (those that inhibit or destroy a retrovirus such as HIV), e.g. didanosine, stavudine and indinavir (a drop in your white cell count may occur),
- myelosuppressive medicines (decrease production of red, white, or coagulating blood cells) and radiation therapy,
- some vaccines (if you have doubts, please ask your pharmacist or your doctor).

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, even medicines obtained without a prescription.

## **Taking Siklos with food and drink**

Please take Siklos in the morning before breakfast, with a glass of water or a very small amount of food.

## **Pregnancy, breast-feeding and fertility**

Siklos is not recommended during pregnancy. Please contact your doctor if you think you may be pregnant. The use of effective contraception is strongly recommended.

If you become pregnant or plan to become pregnant while taking Siklos, your doctor will discuss with you the potential benefits and risks of continuing using Siklos.

For the male patients taking Siklos, if your partner becomes pregnant or plans to become pregnant, your doctor will discuss with you the potential benefits and risks of continuing using Siklos.

The active substance of Siklos passes into human breast-milk. You must not breast-feed while taking Siklos.

## **Driving and using machines**

Some people may experience dizziness when using Siklos.. Do not drive or use any tools or machines if you experience dizziness whilst taking Siklos.

### **3. How to take Siklos**

#### **Dose**

Always take Siklos exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

**Your doctor will tell you how much of Siklos to take each day and will describe the dose in whole, half or quarter tablets.**

The prescribed dose of Siklos must be taken once daily, preferably in the morning before breakfast. If necessary, it can be taken with a glass of water or a very small amount of food.

If you cannot swallow the tablets, you can disintegrate them in water **immediately before use**:

- Place the required dose (preferably broken if Siklos 1000 mg tablet is used) in a teaspoon and add some water.
- As soon as the tablet is disintegrated, swallow the content of the teaspoon. You can add a drop of syrup or mix the content with food to mask a possible bitter taste.
- Then drink a large glass of water or any other drink.

#### **Handling**

Siklos is a medicine that must be handled with care.

Any person, in particular pregnant women, who are not taking Siklos should avoid direct contact with the parts when breaking a tablet. Wash your hands before and after contact with the tablets.

In case the prescribed dose requires breaking the tablet in halves or quarters, this should be done out of the reach of food. Powder spilled from the broken tablet should be wiped up with a damp disposable towel which must be thrown out. For the storage of unused broken tablets, see HOW TO STORE SIKLOS.

#### **Treatment follow-up**

Your doctor will tell you how long to take Siklos for

**When taking Siklos you will have regular blood tests and check your liver and kidney.  
Depending on the dose you take, these tests may be performed every two weeks or every two months.** Depending on these results your doctor will adjust your dose of Siklos.

The growth of children using Siklos should be regularly monitored by the treating doctor.

#### **If you take more Siklos than you should**

If you take more Siklos than you should or if a child has taken any, contact your doctor or the nearest hospital immediately as you may need urgent medical treatment. The most common symptoms of overdose with Siklos are:

- Redness of the skin
- Soreness (touch is painful) and swelling of the palms of hands and soles of feet followed by the hands and feet becoming scaly
- Skin becoming strongly pigmented (locally changes of colour)
- Soreness or swelling in the mouth.

#### **If you forget to take Siklos**

Do not take a double dose to make up for a forgotten tablet. Continue as normal when it is time to take the next dose as prescribed by your doctor.

#### **If you stop taking Siklos**

Do not stop your treatment unless advised by your doctor.

If you have any further question on the use of this medicine, ask your doctor or pharmacist.

#### 4. Possible side effects

Like all medicines, Siklos can cause side effects, although not everybody gets them.

#### ACTIONS TO TAKE IN CASE OF SIDE EFFECTS

**Tell your doctor immediately if you experience any of the following:**

- A severe infection
- Tiredness and/or looking pale
- Unexplained bruising (accumulation of blood under the skin) or bleeding
- Unusual headache
- Difficulties in breathing.

All these are serious side effects of Siklos. You may need medical attention.

**Tell your doctor as soon as possible if you notice any of the following side effects of Siklos:**

- Rash (itching red eruption of the skin)
- Ulcers or wounds on your legs
- Sore (open skin infection) on your skin.
- Fever or chills
- Feeling sick, or a general feeling of being unwell
- Disorientation (confusion) and dizziness

#### DETAILS OF SIDE EFFECTS

**Very common side effects (may affect more than 1 in 10 people):**

Low blood cell counts (myelosuppression), enlargement of red blood cells, decreased resistance to infections.

Absence or low amount of sperm in the semen (azoospermia or oligospermia). Siklos may hence decrease the ability of men to father children.

**Common side effects (may affect up to 1 in 10 people):**

Reduced number of red blood cells (anaemia), low platelet count, headache, skin reactions, inflammation or ulceration of the mouth (oral mucositis).

**Uncommon side effects (may affect up to 1 in 100 people):**

Dizziness, nausea, itching red eruption of the skin (rash), black nails (melanonychia), and hair loss.

**Rare side effects (may affect up to 1 in 1,000 people):**

Wounds on the legs (leg ulcers), and modification of liver function,

**Very rare side effects (may affect up to 1 in 10,000 people) or unknown frequency (frequency cannot be estimated from the available data):**

Isolated cases of malignant disease of blood cells (leukaemia), skin cancer in elderly patients, viral infection with *Parvovirus B19*, bleeding, gastrointestinal disturbances, vomiting, skin dryness, fever, absence of menstrual cycles (amenorrhoea), and weight gain.

#### Reporting of side effects

**If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.**

You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

## **5. How to store Siklos**

Keep this medicine out of the sight and reach of children.

Do not use Siklos after the expiry date which is stated on the carton and the bottle after EXP. The expiry date refers to the last day of that month.

Store below 30°C.

Unused Siklos 1000 mg broken tablets must be replaced in the bottle and must be used within three months.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

## **6. Contents of the pack and other information**

### **What Siklos contains**

The active substance is hydroxycarbamide.

Each Siklos 100 mg film-coated tablet contains 100 mg hydroxycarbamide.

Each Siklos 1000 mg film-coated tablet contains 1,000 mg hydroxycarbamide.

The other ingredients are sodium stearyl fumarate, silicified microcrystalline cellulose and methacrylate copolymer.

### **What Siklos looks like and contents of the pack**

Siklos 100 mg film-coated tablets are off-white, round tablets.

Each tablet is embossed 100 on one side.

Siklos 100 mg is supplied in plastic bottles containing 60, 90 or 120 tablets.

Siklos 1000 mg film-coated tablets are off-white, capsule-shaped tablets marked with three score lines on both sides. The tablet can be divided into four equal parts.

Siklos 1000 mg is supplied in plastic bottle of 30 tablets.

All pack sizes may not be marketed.

### **Marketing Authorisation Holder**

Addmedica  
101 rue Saint Lazare  
75009 Paris  
France

### **Manufacturer**

Delpharm Lille  
Z.I de Roubaix Est  
Rue de Toufflers  
59390 Lys-Lez-Lannoy  
France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**

Nordic Pharma  
Laanstraat 16  
B-2610 Wilrijk  
Tel : +32 (0)3 820 52 24

**Luxembourg/Luxemburg**

Nordic Pharma  
Laanstraat 16  
B-2610 Wilrijk  
België/Belgique/Belgien  
Tel : +32 (0)3 820 52 24

**България**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Франция  
Tel : +33 (0)1 72 69 01 86

**Magyarország**

Addmedica  
101 rue Saint Lazare  
75009 Párizs - Franciaország  
Tel : +33 (0)1 72 69 01 86

**Česká republika**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Francie  
Telefon: +33 (0)1 72 69 01 86

**Malta**

Addmedica  
101 rue Saint Lazare  
75009 Parigi - Franzia  
Tel : +33 (0)1 72 69 01 86

**Danmark**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Frankrig  
Telefon: +33 (0)1 72 69 01 86

**Nederland**

Nordic Pharma B.V.  
Tolweg 15,  
3741 LM Baarn  
Tel.: +31 (0)35-5480580  
Email: [info@nordicpharma.nl](mailto:info@nordicpharma.nl)

**Deutschland**

Nordic Pharma GmbH  
Fraunhoferstrasse 4  
85737 Ismaning  
Tel.: +49 (0)89 88 96 90 680

**Norge**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Frankrike  
Tel : +33 (0)1 72 69 01 86

**Eesti**

Addmedica  
101 rue Saint Lazare  
75009 Pariis - Prantsusmaa  
Tel : +33 (0)1 72 69 01 86

**Österreich**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Frankreich  
Tel : +33 (0)1 72 69 01 86

**Ελλάδα**

DEMO ABEE  
Τηλ.: +30 210 81 61 802

**Polska**

Addmedica  
101 rue Saint Lazare  
75009 Paryż - Francja  
Tel : +33 (0)1 72 69 01 86

**España**

Laboratorios Farmacéuticos ROVI, S.A.  
Tel: +34 91 375 62 30

**Portugal**

Laboratórios Farmacêuticos ROVI, S.A.  
Tel: +351 213 105 610

**France**

Addmedica  
101 rue Saint Lazare  
75009 Paris  
Tel : +33 (0)1 72 69 01 86

**România**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Franța  
Tel : +33 (0)1 72 69 01 86

**Ireland**

Nordic Pharma.  
Tel : +353 (0)14004141  
Email : info@nordicpharma.ie

**Ísland**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Frakkland  
Tel : +33 (0)1 72 69 01 86

**Italia**

Addmedica  
101 rue Saint Lazare  
75009 Parigi - Francia  
Tel : +33 (0)1 72 69 01 86

**Kύπρος**

The Star Medicines Importers Co Ltd  
Τηλ.: +357 25 37 1056

**Latvija**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Francija  
Tel : +33 (0)1 72 69 01 86

**Lietuva**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Prancūzija  
Tel : +33 (0)1 72 69 01 86

**This leaflet was last approved in .**

Detailed information on this medicine is available on the European Medicines Agency website  
<http://www.ema.europa.eu/>. There are also links to other websites about rare diseases and treatments.

**Slovenija**

Addmedica  
101 rue Saint Lazare  
75009 Pariz - Francija  
Tel : +33 (0)1 72 69 01 86

**Slovenská republika**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Francúzsko  
Tel : +33 (0)1 72 69 01 86

**Suomi/Finland**

Addmedica  
101 rue Saint Lazare  
75009 Pariisi -Ranska  
Tel : +33 (0)1 72 69 01 86

**Sverige**

Addmedica  
101 rue Saint Lazare  
75009 Paris - Frankrike  
Tel : +33 (0)1 72 69 01 86

**United Kingdom**

Nordic Pharma Ltd.  
Reading, Berkshire RG7 4SA - UK  
Tel : +44 (0)118 929 82 33

## **Annex IV**

### **SCIENTIFIC CONCLUSIONS AND GROUNDS RECOMMENDING THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION**

## **Scientific conclusions**

Taking into account the PRAC Assessment Report on the PSUR for Siklos, the scientific conclusions of PRAC are as follows:

“Preliminary results of the HYDREP study were provided in March 2013. Sperm results were available for the majority of patients: 63% of the trial population, corresponding to 31 patients of the 49 patients included, for whom follow-up sperm results after 6 months of hydroxycarbamide treatment were available. The preliminary results show that there is a statistically significant impairment in all sperm parameters after a 6 months HU therapy. The rapporteur acknowledges that these results may vary with the final analysis. However they are evocative of a risk of male fertility impairment after 6 months of treatment with SIKLOS. In view of available data, the PRAC considers that the changes to the product information proposed by the MAH should be amended. The frequency of azoospermia and oligospermia in the SmPC/PL should be changed from “very rare” to “very common”. The proposed changes to sections 4.6 and 4.8 of the SmPC and the leaflet are detailed in Annex 1 of this assessment report. However, a further update to the SmPC might be needed, if final study results become available in 2014.”

The CHMP agrees with the scientific conclusions made by the PRAC.

## **Grounds recommending the variation to the terms of the Marketing Authorisation**

On the basis of the scientific conclusions for Siklos, the CHMP is of the opinion that the benefit-risk balance of the medicinal product containing the active substance HYDROXYCARBAMIDE is favourable subject to the proposed changes to the product information.